Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Arctigenin decreased proliferation in colorectal cancer cells with no significant effect on normal cells. حسب Xiang-Fan Chen (13932983)

Study-related adverse events. حسب Benjamin R. Lewis (22279166)

"…In a linear mixed model analysis (LMM), the MBSR + PAP arm evidenced a significantly larger decrease in QIDS-SR-16 score than the MBSR-only arm from baseline to 2-weeks post-intervention (between-groups effect = 4.6, 95% CI [1.51, 7.70]; <i>p</i> = 0.008). …"

Sobel test for the significance of the mediation effect. حسب Getachew Magnar Kitila (19935139)

Most significant muscle activation values. حسب María Benito-de-Pedro (22057468)

الموضوعات:

Significant repeated measurements sEMG outcomes. حسب María Benito-de-Pedro (22057468)

الموضوعات:

Significant single measurement sEMG outcomes. حسب María Benito-de-Pedro (22057468)

الموضوعات:

Modified version of the Caregiving Stress Model for Post Intensive Care Syndrome – Family impairments. حسب Cristobal Padilla-Fortunatti (21376807)

الموضوعات:

SPIRIT schedule: Timeline of recruitment and assessment. <i>t</i>₀: Daily screening; <i>t</i>₁: Between the 3^rd and 10^th day of ICU admi... حسب Cristobal Padilla-Fortunatti (21376807)

الموضوعات:

Questionnaire description. حسب Cristobal Padilla-Fortunatti (21376807)

الموضوعات:

Variables and generalized linear mixed models to explore PICS-F impairments. حسب Cristobal Padilla-Fortunatti (21376807)

الموضوعات:

Decrease of cellular cAMP levels in response to a concentration range of melatonin treatments. حسب Cathryn S. D. Maienza (20629929)

Adverse cardiovascular events by immune checkpoint inhibitor. حسب Jennifer M. Kwan (3350321)

الموضوعات: